TickerKhojMedical Devices & Supplies · Medical Distributors · NSE: VIVOBIOT · data 2026-11-02
Vivo Bio Tech Ltd.
In plain words
Price: 33.3% below its 52-week high of ₹20.94.
Delivery: 77.2% of traded shares were kept for delivery over the last 10 sessions, against 81.9% over the last 53.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹55 cr |
| Net profit (last 12 months) | ₹-3 cr |
| Sales growth, 3 years (yearly) | 0.7% |
| Profit growth, 3 years (yearly) | — |
At a glance
ROE -2.0%, ROCE 8.3%, operating margin 17.2%: how much profit it earns on the money it uses.
Debt/equity 0.72, Profit growth — and sales growth 0.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (-2.0%).
- Slow sales growth (0.7% a year over 3 years).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
22/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 17/30: Delivery 70.7% over the last 20 sessions vs 86.3% in the 40 before (0.82x); shares delivered per day 1.86x usual; 3 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Vivo Bio Tech Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.72.
What is the 52-week high and low of Vivo Bio Tech Ltd.?
The 52-week high is ₹20.94 and the 52-week low is ₹12.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Vivo Bio Tech Ltd. | ₹13.97 | ₹31 cr | — | — | -2% | 8.3% | 0.72 | -30.7% |
| QMS Medical Allied Services Limited | ₹179.75 | ₹350 cr | 31.4 | — | 10.5% | 18.9% | 0.71 | +65.0% |
| Vijaypd Ceutical Limited | ₹76 | ₹149 cr | 29.5 | 2.8 | 11.8% | 9.2% | 0.7 | +68.9% |
| Balaxi Pharmaceuticals Limited | ₹19.95 | ₹106 cr | — | — | 0.6% | — | 0.23 | -53.5% |
| Aakaar Medical Technologies Limited | ₹73 | ₹101 cr | 15.6 | 1.9 | 17.1% | 25.8% | 0.34 | -16.0% |
| Mono Pharmacare Limited | ₹9.2 | ₹16 cr | 46.1 | 0.5 | 2.3% | 7.6% | 1.77 | -53.2% |
Compare VIVOBIOT with QMSMEDI in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VIVOBIOT in TickerKhoj →